Special report: Evidence on sequencing of conventional and biological disease-modifying anti-rheumatic drugs
BlueCross BlueShield Association
Record ID 32004000082
English
Authors' objectives:
This report overviews the literature on 3 key issues: 1) when to start disease-modifying anti-rheumatic drugs (DMARDs); 2) monotherapy versus combination regimens; and 3) optimal DMARD regimens. A primary objective is to determine whether evidence from randomized, comparative trials shows that biological DMARDs are superior to conventional DMARDs for first-line treatment of early, active rheumatoid arthritis (RA).
Authors' methods:
Systematic review
Details
Project Status:
Completed
URL for project:
http://www.bcbs.com/blueresources/tec/contact-tec.html
Year Published:
2003
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Antirheumatic Agents
- Arthritis, Rheumatoid
Contact
Organisation Name:
BlueCross BlueShield Association
Contact Address:
BlueCross BlueShield Association, Technology Evaluation Center, 225 North Michigan Ave, Chicago, Illinois, USA. Tel: 888 832 4321
Contact Name:
tec@bcbsa.com
Contact Email:
tec@bcbsa.com
Copyright:
BlueCross BlueShield Association (BCBS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.